Ming‐Dauh Wang

Learn More
AIMS Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under development for reducing cardiovascular events in patients with high risk vascular disease. CETP inhibitors are likely to be utilized as 'add-on' therapy to statins in patients receiving concomitant medications, so the potential for evacetrapib to cause clinically important(More)
STUDY OBJECTIVE To examine the effect of increased gastric pH on exposure to evacetrapib, a cholesteryl ester transfer protein inhibitor evaluated for the treatment of atherosclerotic heart disease. DESIGN Open-label, two-treatment, two-period, fixed-sequence crossover study. SETTING Clinical research unit. SUBJECTS Thirty-four healthy subjects. (More)
  • 1